Our predictive models process a wide spectrum of data

Combining multiple data sources, we have created more informed markers of response

In cancer care, clinicians use bio-markers to predict how well a patient may respond to immunotherapy treatment. Until now, these bio-markers have been based on just one factor within a cell and so the expected outcome is often unreliable.

The Curenetics AI tool combines many complex data sources to produce a highly informed bio-marker that predicts a patient’s response with great accuracy. The advanced bio-markers that we have been able to identify will increase certainty in how patients will respond to treatment.

Advantages of the Curenetics AI tool:

  • The data used within our tool combines genomic, histopathological, and clinical information in a way that has not been done before. This layering of data improves the accuracy of our predictions.

  • Around the globe, different populations have subtly different characteristics that affect their risk profile. Our tool is trained on the closest data available for the local population of our users. This accounts for these population variations, providing more individualised results.

  • Immune checkpoint inhibitors is currently the fastest growing segment of cancer immunotherapy. Our team keeps up to date with advances, developing our tool to incorporate new bio-markers.

  • Our partner organisations provide expertise that contributes directly to Curenetics research and validates the accuracy of our results.